Survival analysis
In the survival analysis, median survival could not be reached as at
least 50% of the patients did not die in the overall survival
calculation. From the available data, it was concluded that 77.6% of
the patients (95% CI:77.50-77.69) had an overall survival longer than
95 months. The RFS time of the patients was calculated as 107 months on
average. There was no significant relationship between patient age and
RFS (p>0.05).
When the effect of GSs and GGs on overall survival was investigated, no
statistical significance was found (p>0.05), however, the
effect on RFS was statistically significant (p<0.001). The
survival curves for these results are given in Figure 3.
The median survival of the patients in the pT2 stage was 107 months,
50.8% of those in the pT3a stage had a survival of 81±0.2 months, and
the survival of 81% of those in the pT3b stage was 50±0.1 months. The
pathological stage showed a statistically strong and significant
relationship with RFS (Figure 4).
As for the effect of HP evaluation results on RFS; a statistically
significant correlation was found between the presence of EPE, PNI, LVI,
SMP, tumor volume, and RFS (p<0.001), but not with the
presence of HGPIN (p>0.05). HP evaluation results and RFS
curves are given in Figure 5. In the evaluations made according to the
HP patterns, the relationship between the presence of the cribriform
glands, a morphological subtype of pattern 4, and RFS was found to be
statistically significant (p<0.001). RFS decreased as the
incidence of cribriform glands increased. The relationship curve between
the presence of the cribriform glands and RFS is given in Figure 6.